Back to results
US 8,008,086 B2Granted
Protocol for monitoring direct thrombin inhibition
AssigneeCora Healthcare, Inc.
InventorsEli Cohen, Roslyn Cohen
Life of this patent
Estimating the term…
Abstract
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies.
Claims10
A method of evaluating patient hemostasis therapy the method comprising:
- testing by thrombelastography a first whole blood sample obtained from a subject to determine a first time-based, clot strength related quantitative indication of a blood sample hemostasis characteristic, the first blood sample being obtained from the subject prior to in vivo administration of the hemostasis therapy;
- testing by thrombelastography a second whole blood sample obtained from the subject to determine a second time-based, clot strength related quantitative indication of the blood sample hemostasis characteristic, the second blood sample being obtained from the subject following in vivo administration of the hemostasis therapy;
- and
- determining a parameter indicative of the efficacy of the hemostasis therapy based upon the first and second quantitative indications, wherein the hemostasis therapy comprises a direct thrombin inhibition therapy and at least one of the first blood sample and the second blood sample is prepared prior to testing to include in vitro administration of a prothrombin activator.
1 more element
Dependencies are inferred from the claim text.